1. Home
  2. RDI vs TIL Comparison

RDI vs TIL Comparison

Compare RDI & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Reading International Inc

RDI

Reading International Inc

SELL

Current Price

$1.82

Market Cap

49.0M

ML Signal

SELL

Logo Instil Bio Inc.

TIL

Instil Bio Inc.

SELL

Current Price

$5.49

Market Cap

52.2M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
RDI
TIL
Founded
1937
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Movies/Entertainment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
49.0M
52.2M
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
RDI
TIL
Price
$1.82
$5.49
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
27.0K
★ 72.1K
Earning Date
11-16-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 60.76
N/A
EPS
★ N/A
N/A
Revenue
★ $202,988,000.00
N/A
Revenue This Year
$15.10
N/A
Revenue Next Year
$4.04
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.94
$5.28
52 Week High
$2.41
$13.50

Technical Indicators

Market Signals
Indicator
RDI
TIL
Relative Strength Index (RSI) 53.66 31.93
Support Level $1.64 N/A
Resistance Level $2.13 $7.67
Average True Range (ATR) 0.12 0.49
MACD 0.03 -0.08
Stochastic Oscillator 65.85 17.13

Price Performance

Historical Comparison
RDI
TIL

About RDI Reading International Inc

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.

About TIL Instil Bio Inc.

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

Share on Social Networks: